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Abstract	
	
Inhibition	of	neurohumoral	pathways	such	as	the	renin	angiotensin	aldosterone	and	
sympathetic	nervous	systems	is	central	to	the	understanding	and	treatment	of	heart	failure.	
Conversely,	until	recently,	potentially	beneficial	augmentation	of	neurohumoral	systems	
such	as	the	natriuretic	peptides	has	had	limited	therapeutic	success.	Administration	of	
synthetic	natriuretic	peptides	has	not	improved	outcomes	in	acute	heart	failure	but	
modulation	of	the	natriuretic	system	through	inhibition	of	the	enzyme	that	degrades	
natriuretic	(and	other	vasoactive)	peptides,	neprilysin,	has	proven	to	be	successful.	After	
initial	failures	with	neprilysin	inhibition	alone	or	dual	neprilysin-ACE	inhibition,	the	
Prospective	comparison	of	ARNI	with	ACEI	to	Determine	Impact	on	Global	Mortality	and	
morbidity	in	Heart	Failure	trial	(PARADIGM-HF)	trial	demonstrated	that	morbidity	and	
mortality	can	be	improved	with	the	angiotensin	receptor	blocker	neprilysin	inhibitor	
sacubitril/valsartan	(formerly	LCZ696).	In	comparison	to	the	ACE	inhibitor	enalapril,	
sacubitril/valsartan	reduced	the	occurrence	of	the	primary	endpoint	(cardiovascular	death	
or	hospitalisation	for	heart	failure)	by	20%	with	a	16%	reduction	in	all-cause	mortality.	
These	findings	suggest	that	sacubitril/valsartan	should	replace	an	ACE	inhibitor	or	
angiotensin	receptor	blocker	as	the	foundation	of	treatment	of	symptomatic	patients	(NYHA	
II-IV)	with	heart	failure	and	a	reduced	ejection	fraction.	This	review	will	explore	the	
background	to	neprilysin	inhibition	in	heart	failure,	the	results	of	the	PARADIGM-HF	trial	
and	offer	guidance	on	how	to	use	sacubitril/valsartan	in	clinical	practice.		
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The	renin	angiotensin	aldosterone	system	(RAAS)	system	is	at	the	core	of	the	
pathophysiology	of	heart	failure	and	its	modulation	is	central	to	altering	the	disease	process	
in	heart	failure	with	reduced	ejection	fraction	(HF-REF).	Successive	randomised	controlled	
trials	have	demonstrated	that	blockade	of	the	RAAS	improves	not	only	morbidity,	but	also	
mortality,	in	patients	with	HF-REF.	1–3	The	prognosis	of	HF-REF	has	been	improved	as	a	
consequence,	although	it	remains	poor	4	as	it	remains	a	complex	syndrome	involving	a	
multitude	of	neurohormonal	pathways.	Therefore,	further	therapies	to	improve	outcomes	
in	these	patients	are	needed.		
	
The	natriuretic	peptide	system	
The	natriuretic	peptide	system	counter	regulates	the	detrimental	effects	of	the	up-
regulation	of	the	RAAS	that	occurs	in	HF-REF,	inhibits	secretion	of	arginine	vasopressin	and	
modulates	the	autonomic	nervous	system	in	ways	that	are	likely	to	be	beneficial	in	this	
syndrome.5	Sodium	and	water	retention	and	vasoconstriction	caused	by	activation	of	the	
RAAS	and	sympathetic	nervous	system,	and	the	action	of	vasopressin,	lead	to	increased	
ventricular	pre-load	and	afterload	and	elevated	wall	stress	which	in	turn	lead	to	production	
of	pre-pro	B-type	natriuretic	peptide	which	is	cleaved	to	B-type	natriuretic	peptide	(BNP)	
and	N-terminal	proBNP	(NT-proBNP).	The	release	of	natriuretic	peptides	may	also	be	
determined	by	the	levels	of	other	neurohormones	such	as	angiotensin	II	and	endothelin	6.	
The	peptide	BNP	acts	to	promote	natriuresis	and	vasodilation	(NT-proBNP	is	physiologically	
inactive).	Atrial	stretch	leads	to	the	production	of	pre-pro-atrial	or	A-type	natriuretic	
peptide	and	ultimately	atrial	natriuretic	peptide	(ANP)	which	has	similar	biological	
properties	to	BNP.5	Urodilatin	(which	is	structurally	related	to	ANP),	is	derived	from	the	
same	precursor	in	the	kidneys.7	C-type	natriuretic	peptide	(CNP)	is	released	from	
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endothelial	cells	and	acts	in	a	paracrine	fashion	but	is	only	found	in	low	concentrations	in	
circulating	blood.5	Two	strategies	have	been	employed	to	try	and	improve	outcomes	in	HF-
REF	via	modulation	of	this	pathway.	The	first	is	the	administration	of	exogenous	natriuretic	
peptides.	Nesiritide,	a	recombinant	human	BNP,	initially	showed	promising	beneficial	
effects	on	haemodynamics	and	natriuresis	in	patients	with	HF-REF.8	However,	in	a	large	
scale	randomised	controlled	trial,	nesiritide	failed	to	improve	outcomes	(though	it	did	
improve	dyspnoea).9	Although	carperitide	(recombinant	ANP)	is	used	as	a	treatment	for	
acute	heart	failure	in	Japan,	there	is	no	robust	evidence	supporting	this	practice.10	The	
second	strategy	is	to	inhibit	the	breakdown	of	natriuretic	peptides.	ANP,	BNP,	CNP	and	
urodilatin	are	cleaved	and	inactivated	by	a	membrane	bound	endopeptidase,	neprilysin	(as	
well	as	insulin	degrading	enzyme).	Neprilysin	is	found	in	a	number	of	tissues	but	in	
especially	high	concentrations	in	the	kidney.	Natriuretic	peptides	are	also	cleared	via	the	
natriuretic	peptide	clearance	receptor	(NPRC	and	NPRC3).	
	
Initial	neprilysin	inhibitors	
Initial	attempts	at	inhibiting	neprilysin	using	an	oral	(racecodotril	11)	and	intravenous	
(candoxatrilat	12)	formulation	were	successful	in	promoting	natriuresis	and	increasing	
urinary	excretion	of	ANP.	A	further	neprilysin	inhibitor	(ecadotril)	had	similar	effects.13	
However,	a	study	of	chronic	use	of	the	oral	pro-drug	candoxatril	showed	that	the	initial	
reduction	in	blood	pressure	was	not	sustained	and	therefore	development	was	stopped.14	
This	might	be	explained	by	the	finding	that	neprilysin	also	breaks	down	angiotensin	II.15–17	
Therefore	inhibiting	neprilysin	alone,	while	raising	natriuretic	peptides	levels,	also	increases	
angiotensin	II	levels	(and	other	substrates	for	neprilysin	such	as	endothelin,	vasopressin,	
bradykinin	etc)	potentially	counteracting	the	actions	of	the	former	peptides.		
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Dual	neprilysin	and	angiotensin	converting	enzyme	inhibition	
The	solution	to	the	problem	of	lone	neprilysin	inhibition	appeared	to	be	dual	blockade	of	
the	RAAS	and	natriuretic	peptide	system	(Figure	1).	As	ACE	inhibitors	are	known	to	improve	
outcomes	it	seemed	logical	to	combine	an	ACE	inhibitor	with	a	neprilysin	inhibitor.	The	
combined	ACE	and	neprilysin	inhibitor	omapatrilat	was	studied	in	a	large	randomized	
controlled	trial	against	enalapril	10mg	twice	daily	in	the	Omapatrilat	Versus	Enalapril	
Randomized	Trial	of	Utility	in	Reducing	Events	(OVERTURE)	trial.18	The	primary	endpoint,	
death	from	any	cause	or	heart	failure	hospitalizations	were	not	reduced	by	omapatrilat.	
Although	other	secondary	endpoints	suggested	a	benefit	with	omapatrilat	(death	from	any	
cause	or	CV	hospitalization	was	9%	lower	in	the	omapatrilat	group)	the	rate	of	angioedema	
was	much	higher	in	the	omapatrilat	group.	Both	ACE	and	neprilysin	break	down	bradykinin	
and	omapatrilat	also	inhibits	aminopeptidase	P	which	also	catabolises	bradykinin.	
Therefore,	unintended	excessive	potentiation	of	bradykinin	and	resultant	high	rates	of	
serious	angioedema	led	to	the	discontinuation	of	the	clinical	development	of	this	drug.		
	
Angiotensin	receptor	blocker	neprilysin	inhibitors	(ARNi)	
Combining	an	angiotensin	receptor	blocker	(ARB)	and	a	neprilysin	inhibitor	was	the	logical	
next	step	and	potential	solution	to	the	problem	encountered	with	omapatrilat.	The	
angiotensin	receptor	neprilysin	inhibitor	(ARNi)	sacubitril/valsartan	(formerly	known	as	
LCZ696)	was	designed	with	the	aim	of	inhibiting	neprilysin	while	blocking	the	adverse	
effects	of	the	RAAS	and	reducing		bradykinin	potentiation.19–21	The	drug	LCZ696	is	made	of	
the	angiotensin	receptor	blocker	valsartan	and	neprilysin	inhibitor	pro-drug	sacubitril.	As	
the	active	metabolite	of	sacubitril,	LBQ657,	does	not	inhibit	aminopeptidase	P,	the	risk	of	
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angioedema	was	expected	to	be	lower	than	with	omapatrilat.19–21	Given	twice	daily,	
sacubitril/valsartan	leads	to	sustained	neprilysin	and	RAAS	inhibition	over	a	24	hour	period	
addressing	one	limitation	of	the	OVERTURE	trial	in	which	omapatrilat	was	given	as	a	single	
large	dose	once	daily.22	That	approach	may	have	contributed	to	the	significant	early	post-
dose	hypotension	seen	with	omapatrilat	but	did	not	provide	sustained	inhibition	ACE	and	
neprilysin	over	24	hours.	The	systemic	exposure	delivered	by	sacubitril/valsartan	200mg	is	
equivalent	to	160mg	of	valsartan	and	neprilysin	is	almost	completely	inhibited	for	up	to	12	
hours.19–21		
	
The	Prospective	comparison	of	ARNI	with	ACEI	to	Determine	Impact	on	Global	Mortality	and	
morbidity	in	Heart	Failure	trial	(PARADIGM-HF)	was	conducted	to	test	whether	200mg	twice	
daily	of	sacubitril/valsartan	was	superior	to	enalapril	10mg	twice	daily	in	reducing	the	
primary	endpoint	of	cardiovascular	death	or	heart	failure	hospitalization.22–24	All	
randomized	patients	completed	a	run-in	period	of	6-8	weeks	during	which	it	was	required	
that	the	target	dose	of	both	drugs	was	tolerated	prior	to	randomisation.	Each	treatment	
period	(enalapril	and	sacubitril/valsartan)	included	a	washout	period	to	avoid	simultaneous	
neprilysin	and	ACE	inhibition	and	the	potential	risk	of	angioedema	(patients	with	a	history	of	
angioedema	were	also	excluded).	The	trial	was	terminated	early,	on	the	recommendation	of	
the	Data	Monitoring	Committee,	due	to	a	sustained	and	highly	significant	reduction	in	the	
risk	of	the	primary	composite	endpoint	(cardiovascular	death	or	heart	failure	
hospitalization)	and	in	cardiovascular	mortality	in	the	sacubitril/valsartan	group	compared	
with	the	enalapril	group.	At	the	end	of	the	trial,	there	was	a	20%	relative	risk	reduction	in	
the	primary	endpoint	and	each	of	its	components,	as	well	as	a	16%	reduction	in	all-cause	
mortality.	The	two	major	modes	of	cardiovascular	death,	sudden	death	and	death	from	
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worsening	heart	failure,	were	equally	and	significantly	reduced.25	Both	first	hospitalisations	
for	heart	failure	and	total	(including	repeat)	hospitalisations	were	also	reduced	by	21%	and	
23%	respectively	(Figure	2).26	Therefore,	for	every	1000	patients	switched	from	enalapril	to	
sacubitril/valsartan,	over	a	median	of	27	months,	there	would	be:	47	less	primary	endpoints	
(CV	death	or	heart	failure	hospitalisations),	33	less	cardiovascular	deaths,	28	less	first	
hospitalisations	for	heart	failure	(53	less	total	hospitalisations	for	heart	failure)	and	32	less	
deaths	from	any	cause.24	No	convincing	or	consistent	interaction	between	any	of	the	
subgroups	and	study	outcomes	were	observed.24	There	was	no	statistically	significant	
difference	in	the	rate	of	angioedema	with	sacubitril/valsartan	although	numerically	more	
cases	were	observed	than	in	the	enalapril	group	(19	patients	in	the	sacubitril/valsartan	
group	and	10	cases	in	the	enalapril	group,	p=0.13)24.	Hypotension	was	significantly	more	
common	with	sacubitril/valsartan	than	with	enalapril	(14%	vs.	9%	in	the	in	the	
sacubitril/valsartan	and	enalapril	groups	respectively,	p<0.001),	although	this	rarely	led	to	
study-drug	discontinuation	(0.9%	and	0.7%	in	the	sacubitril/valsartan	and	enalapril	groups	
respectively,	p=0.38).		Conversely,	renal	dysfunction,	hyperkalaemia	and	cough	were	less	
common	with	sacubitril/valsartan	than	with	enalapril.	Subsequent	analyses	of	PARADIGM-
HF	have	confirmed	that	the	relative	reductions	in	morbidity	and	mortality	and	differential	
rates	of	adverse	events	were	similar	across	all	ages	27	(Figure	3)	and	baseline	risk	of	death	as	
determined	by	risk-scoring	systems.28		
	
Robustness	of	results	of	PARADIGM-HF	and	regulatory	approval	
Regulatory	approval	of	a	new	drug	requires	demonstration	of	effectiveness	and	safety	in	
either	two	trials	with	a	2-sided	P<0.05	OR	a	single,	large,	internally	consistent,	multicentre	
study	with	p<0.00125.29	PARADIGM-HF	fulfils	these	criteria.	It	was	large	(8399	patients	
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randomised),	highly	statistically	significant	(p=0.0000004),	internally	consistent	(lack	of	
subgroup	interactions),	multicentre	(sites	were	located	in	47	countries),	and,	there	were	
large	effects	on	morbidity	and	mortality	(cardiovascular	death	or	hospitalisation	for	heart	
failure	was	reduced	by	20%	and	all-cause	mortality	by	16%).	If	we	ignore	the	argument	that	
to	repeat	the	trial	would	be	unethical,	to	achieve	such	a	statistically	significant	result	on	the	
primary	endpoint	would	require	4	or	5	trials	each	with	a	p	value	of	<0.05	to	have	the	same	
strength	of	evidence	as	provided	by	a	single	trial	with	a	p	value	=	0.0000004	(Table	1).	Put	
another	way,	if	sacubitril/valsartan	was	in	fact	no	better	than	enalapril	the	chances	of	
observing	the	treatment	difference	that	was	found	in	PARADIGM-HF	is	less	than	1	in	a	
million.30		We	believe	that	this	finding	creates	a	unique	question	for	heart	failure	guideline	
committee.	“Level	A”	evidence	conventionally	requires	data	from	multiple	randomised	trials	
or	a	well	conducted	meta-analysis	(Table	2).	Usually,	a	solitary	randomized	trial	would	
confer	a	B	level	of	evidence.	Does	the	robustness	of	the	findings	of	PARADIGM-HF	equate	to	
two	trials	or	a	meta-analysis?	
	
Who	should	be	prescribed	sacubitril/valsartan?	
The	only	evidence	for	the	use	of	sacubitril/valsartan	is	in	patients	with	HF-REF.	An	outcomes	
trial	of	sacubitril/valsartan	versus	valsartan	in	patients	with	heart	failure	and	preserved	
ejection	fraction,	the	Prospective	comparison	of	ARni	with	Arb	Global	Outcomes	in	heart	
failure	with	preserved	ejectioN	fraction	(PARAGON-HF)	is	currently	still	recruiting	
(ClinicalTrials.gov	Identifier:NCT01920711).	We	also	do	not	have	robust	data	on	the	use	of	
this	drug	in	hospitalised	patients	(although	some	data	are	available31	a	trial	is	underway	
ClinicalTrials.gov	Identifier:	NCT02661217)	or	those	with	HF	complicating	an	acute	
myocardial	infarction.	Therefore,	if	we	consider	the	inclusion	and	exclusion	criteria	of	the	
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PARADIGM-HF	trial,	sacubitril/valsartan	can	be	given	to:	adult	patients	with	heart	failure,	
NYHA	II-IV	and	a	reduced	ejection	fraction	(≤40%)	on	a	beta-blocker	and	MRA	as	
recommended	by	guidelines,	with	a	systolic	blood	pressure	of	≥100	mmHg	and	eGFR	≥30	
ml/min/1.73m2	and	potassium	≤5.2	mmol/l	(Figure	4).	The	US	Food	and	Drug	
Administration	(FDA)	and	European	Medicines	Agency	(EMA)	prescribing	information	is	
consistent	with	these	groups.32,33	Although	further	inclusion	criteria	were	stipulated	in	the	
trial	(patients	had	to	have	a	BNP	≥150	pg/ml	(NTpro-BNP	≥600	pg/ml)	or	if	hospitalised	with	
heart	failure	a	BNP	≥100	pg/ml	(NTpro-BNP	≥400	pg/ml))	these	are	not	part	of	the	FDA	or	
EMA	prescribing	information,	presumably	because	most	patients	with	HF-REF	exceed	these	
thresholds34–36,	because	there	was	no	interaction	between	baseline	natriuretic	peptide	
concentration	and	the	effect	of	treatment	24	and	because	there	is	no	biological	basis	for	
assuming	sacubitril/valsartan	would	lose	its	effectiveness	below	these	thresholds.	
Supporting	the	prescribing	information	from	the	FDA	and	EMA,	cost	effectiveness	analyses	
in	private	37and	public	38,39	health	care	systems	confirm	that	sacubitril/valsartan	is	cost	
effective.		
	
When	should	a	patient	be	prescribed	sacubitril/valsartan?	
Currently	the	prescribing	information	from	the	FDA	notes	that	sacubitril/valsartan	should	be	
used	in	patients	in	place	of	an	ACE	inhibitor	or	other	ARB	i.e.	that	patients	on	these	
treatments	should	be	switched	to	the	ARNI.32	We	are	lacking	evidence	for	patients	with	
newly	diagnosed	HF-REF.	Should	they	be	established	on	an	ACE	inhibitor	(or	ARB)	for	at	least	
one	month	after	which	time	they	would	have	been	eligible	for	PARADIGM-HF	i.e.	to	switch	
to	sacubitril/valsartan?	The	FDA	seems	to	have	decided	otherwise	as	their	labelling	also	
gives	recommendations	on	how	to	start	sacubitril/valsartan	in	ACE	inhibitor/ARB	naïve	
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patients	(see	below).32	This	is	probably	logical	(if	not	entirely	evidence-based),	as	the	lower	
risks	of	renal	dysfunction	and	hyperkalaemia	with	sacubitril/valsartan	may	enable	more	
patients	to	achieve	optimal	RAAS	inhibition.	Furthermore,	conducting	a	trial	in	ACE	
inhibitor/ARB	naïve	patients	would	be	nearly	impossible	–	recruitment	would	be	slow	(given	
the	much	smaller	number	of	incident	heart	failure	patients)	and	cross-over	from	the	ACE	
inhibitor	group	to	the	sacubitril/valsartan	group	is	likely	to	be	very	high	confounding	
interpretation	of	outcomes.	In	the	Safety	and	Tolerability	of	Initiating	LCZ696	in	Heart	
Failure	Patients	(TITRATION)	study		31	of	dose	escalation	strategies	of	sacubitril/valsartan	
(N=498)	patients	who	were	ACE	inhibitor	or	ARB	naïve	(7%)	and	hospitalised	(11%)	were	
included.	Rates	of	adverse	events	were	similar	to	those	reported	in	PARADIGM-HF.	
	
Furthermore,	apart	from	these	practical	considerations,	there	is	no	plausible	scientific	
reason	to	believe	the	results	of	such	a	trial	would	be	different	than	PARADIGM-HF	and	an	
analysis	of	the	PARADIGM-HF	trial	by	subgroup	of	duration	of	HF	(those	with	HF	for	<=1	
year,	1	to	5	years	and	>5	years)	revealed	no	interaction	between	duration	of	heart	failure	
and	benefit	from	sacubitril/valsartan	(p	for	interaction	for	the	primary	outcome	=	0.27).24		
	
How	should	sacubitril/valsartan	be	prescribed?	
Sacubitril/valsartan	should	not	be	given	in	conjunction	with	another	ARB	or	renin	inhibitor	
(because	of	the	risk	of	renal	impairment	and	hyperkalaemia)	or	an	ACE	inhibitor	(risk	of	
renal	impairment,	hyperkalaemia	and	angioedema).	Due	to	the	potential	risk	of	angioedema	
when	used	concurrently	with	an	ACE	inhibitor,	sacubitril/valsartan	must	not	be	started	for	
at	least	36	hours	after	discontinuing	an	ACE	inhibitor.32	Patients	and	carers	should	discard	
any	remaining	doses	to	reduce	the	risk	of	accidental	dosing.	The	starting	dose	of	
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sacubitril/valsartan	is	100mg	twice	daily.	This	should	be	reduced	in	certain	groups	(Table	3).	
The	dose	should	be	doubled	every	2	to	4	weeks	as	tolerated	by	the	patient	to	the	maximum	
dose	of	200mg	twice	daily.		
	
Patients	should	also	be	prescribed	other	evidence-based	drugs	(beta-blocker,	
mineralocorticoid	receptor	antagonist,	ivabradine	and	digoxin)	and	devices	(CRT,	ICD),	as	
appropriate.	
	
Side	effects	and	cautions	
Renal	function	and	potassium	should	be	monitored	as	for	any	other	RAAS	blocker.	Similarly	
blood	pressure	should	also	be	monitored	and	we	would	suggest	that	the	drug	is	not	started	
in	those	with	a	systolic	blood	pressure	of	<100	mmHg	in	keeping	with	the	exclusion	criteria	
of	the	trial.	In	the	event	of	the	development	of	hypotension,	renal	impairment	or	
hyperkalaemia	evaluation	of	the	potential	causes	should	be	sought	and	appropriate	changes	
made.	For	example,	reducing	the	dose	of	other	non-essential	blood	pressure-lowering	
drugs,	adjusting	the	dose	of	diuretics,	discontinuing	other	drugs	such	as	non-steroidal	anti-
inflammatory	drugs.	Of	course	dose	reduction	or	discontinuation	of	sacubitril/valsartan	
should	also	be	considered	in	these	scenarios	after	assessment	of	the	patient.	The	
development	of	angioedema	should	lead	to	immediate	discontinuation	and	treatment	with	
appropriate	therapy	until	it	has	resolved.	Permanent	treatment	discontinuation	was	not	
common	in	the	PARADIGM-HF	trial	with	rates	of	discontinuation	similar	in	the	
sacubitril/valsartan	group	and	enalapril	group	for	hypotension	and	hyperkalaemia	(all	
<1%).24	Rates	of	discontinuation	for	renal	impairment	were	lower	in	the	sacubitril/valsartan	
group	compared	with	the	enalapril	group	(0.7%	vs	1.4%	respectively,	p=0.002).	
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One	final	issue	worthy	of	note	is	that	of	treatment	monitoring.	Monitoring	the	treatment	
and	prognosis	of	patients	with	heart	failure	by	tracking	natriuretic	peptides	is	still	an	area	of	
great	interest.40	Sacubitril/valsartan	increases	levels	of	circulating	BNP	therefore	BNP	is	not	
useful	for	monitoring	prognosis	these	patients.26	NT-proBNP	is	still	useful	as	changes	in	the	
levels	of	this	inactive	peptide	continue	to	reflect	reduced	pre-pro	BNP	secretion	as	a	result	
of	reduction	in	wall-stress.26	Neprilysin	has	a	higher	affinity	for	other	natriuretic	peptides	
such	as	ANP	and	CNP	than	it	does	for	BNP.	Therefore,	other	natriuretic	peptides	may	be	
more	useful	to	monitor	treatment	response	and	the	level	of	neprilysin	inhibition,	although	
whether	this	would	predict	prognosis	is	unclear.	
	
Heart	failure	with	preserved	ejection	fraction	
There	is	also	experience	with	sacubitril/valsartan	in	heart	failure	with	preserved	ejection	
fraction	(HF-PEF).	In	the	Prospective	comparison	of	ARNI	with	ARB	on	Management	Of	heart	
failUre	with	preserved	ejectioN	fracTion	(PARAMOUNT)	trial,	301	patients	with	HF-PEF	were	
randomised	to	valsartan	or	sacubitril/valsartan.41	NT-proBNP	fell	in	the	latter	group	along	
with	reductions	in	NYHA	class	and	left	atrial	volumes.	On	the	basis	of	these	findings	and	the	
favourable	effects	seen	in	PARADIGM-HF	a	large	multicentre	randomised	outcomes	trial	of	
sacubitril/valsartan	versus	valsartan	is	currently	recruiting,	PARAGON-HF.		
	
Summary	
Even	in	HF-REF	patients	with	mild	symptoms,	apparently	“stable”	on	conventional	
treatment,	it	is	clear	that	morbidity	and	mortality	remains	high	and	that	substitution	of	
sacubitril/valsartan	for	an	ACE	inhibitor	leads	to	rapid	and	substantial	improvement	in	
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outcomes.	Therefore,	it	is	our	view	that	an	ARNI	should	replace	an	ACE	inhibitor	(or	an	ARB)	
as	a	foundation	of	treatment	for	HF-REF	and	already	this	view	is	reflected	in	new	guidelines	
42,43	.	The	results	of	the	PARAGON-HF	trial	will	determine	whether	sacubitril/valsartan	has	
any	place	in	the	management	of	HF-PEF.		The	speed	of	adoption	of	sacubitril/valsartan	will	
depend	on	a	number	of	different	factors,	including	cost-effectiveness.		
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Table	1	Number	of	trials	with	a	p	value	<0.05	to	provide	the	same	level	of	evidence	as	
PARADIGM-HF	on	the	primary	outcome	and	cardiovascular	death.	Based	on	the	formula	
(0.025)n	x2	where	n	is	the	number	of	trials	required	(personal	communication	Stuart	
Pocock).		
Number	of	trials	
with	P<0.05	
showing	efficacy		
P	value	required	by	1	trial	
to	provide	the	same	
strength	of	evidence		
PARADIGM-HF	P	
value	for	Primary	
endpoint		
PARADIGM-HF	P	value	
for	CV	Death	
1	trial	 0.05	 	 	
2	trials	*	 0.00125	*	 	 0.00008	(equivalent	to	
2	to	3	trials	at	p<0.05)	3	trials	 0.00003125	 	
4	trials	 0.00000078	 0.0000004	
(equivalent	to	4	to	5	
trials	at	p<0.05)	
	
5	trials	 0.0000000195	 	
*	Usual	regulatory	requirement	–	2	trials	at	P<0.05	OR	1	trial	at	P<0.00125	
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Table	2.	Class	of	recommendation	and	level	of	evidence	definitions	used	by	major	
guideline	bodies.	
		
Classes	of	
recommendations	
Definition	
Class	I	 Evidence	and/or	general	agreement	that	a	given	treatment	or	
procedure	is	beneficial,	useful,	effective	
Class	II	 Conflicting	evidence	and/or	a	divergence	of	opinion	about	the	
usefulness/efficacy	of	the	given	treatment	or	procedure	
						Class	IIa	 Weight	of	evidence	/	opinion	is	in	favour	of	usefulness/	efficacy	
						Class	IIb	 Usefulness/	efficacy	is	less	well	established	by	evidence/	
opinion	
Class	III	 Evidence	or	general	agreement	that	the	given	treatment	or	
procedure	is	not	useful/effective,	and	in	some	cases	may	be	
harmful	
	 	
Levels	of	Evidence	 Definition	
Level	of	evidence	A	 Data	derived	from	multiple	randomized	clinical	trials	or	meta-
analyses	
Level	of	evidence	B	 Data	derived	from	a	single	randomized	clinical	trial	or	large	
non-randomized	studies	
Level	of	evidence	C	 Consensus	of	opinion	of	the	experts	and/	or	small	studies,	
retrospective	studies,	registries	
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Table	3.	Starting	dose	and	dose	titration	for	sacubitril/valsartan	in	a	variety	of	patient	
populations	with	heart	failure	and	reduced	ejection	fraction	
	
Population	with	HF-REF	 Starting	dose	of	
sacubitril/valsartan*	
Up	titration	and	target	
dose	
No	patient	characteristics	requiring	
caution	or	dose	reduction		
100mg	twice	daily	
Up	titration	by	doubling	of	
dose	every	2-4	weeks	until	
a	target	dose	of	200mg	
twice	daily	is	reached	
Currently	only	able	to	tolerate	a	low	
or	submaximal	target	dose	of	ACE	
inhibitor	or	ARB**	
50mg	twice	daily	
No	ACE	inhibitor	or	ARB	in	the	past	 50mg	twice	daily	
eGFR	<30	ml/min/m2¶	 50mg	twice	daily	
Moderate	hepatic	impairment	
(Child	Pugh	Class	B)	
50mg	twice	daily	
Elderly	 50mg	twice	daily	
*	50mg	=	24mg	sacubitril/26mg	valsartan,	100mg	=	49mg	sacubitril/51mg	valsartan,	200mg	
=97	mg	sacubitril/103mg	valsartan	
**Target	doses	of	ACE	inhibitors	and	ARBs	are	as	follows:	ACE	inhibitors	–	captopril	50mg	
t.i.d	,	enalapril	10mg	b.i.d,	lisinopril		20mg	o.d.,	ramipril	5mg	b.i.d.,	trandolopril	4mg	o.d.	
ARBs	–	candesartan	32mg	o.d.,	losartan	150mg	o.d.,	valsartan	160mg	o.d.	
¶	The	European	Medicines	Agency	also	suggests	that	a	dose	of	50mg	(24mg/26mg)	can	be	
considered	if	eGFR	30-60	ml/min/m2	
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Figure	Legends	
	
Figure	1.	Pathways	blocked	by	ACE	inhibitors,	angiotensin	receptor	blockers	and	neprilysin	
inhibitors.		
	
Figure	2.	Effect	of	sacubitril/valsartan	on	the	rate	of	heart	failure	hospitalisations	as	a	
time	to	first	event	analysis	and	as	a	recurrent	event	analysis	of	total	hospitalisations	for	
heart	failure.	26	
	
Figure	3.	Effect	of	sacubitril/valsartan	on	the	rate	of	primary	endpoint	and	component	
and	all-cause	mortality	in	patients	randomised	in	the	PARADIGM-HF	trial	according	to	age	
group.27	P	for	interaction	for	cardiovascular	(CV)	death	or	heart	failure	(HF)	
hospitalisation=0.94,	for	CV	death	p	for	interaction=0.92,	for	HF	hospitalisation	p	for	
interaction=0.81	and	all-cause	death	p	for	interaction=0.99.		
	
Figure	4:	Stepwise	treatment	of	patients	with	symptomatic	(NYHA	II-IV)	heart	failure	with	
reduced	ejection	fraction.	Progressive	therapies	should	be	added	in	a	stepwise	fashion.	
Where	two	or	more	options	exist	on	a	step	the	most	appropriate	therapy	for	the	patient	
based	on	concomitant	medication	or	the	presence	of	other	patient	factors	should	be	
made.				
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